Table 1.

Clinical characteristics of men in the REDUCE trial who had at least one on-study biopsy stratified by obesity status

Normal weight <25 kg/m2Overweight 25–29.9 kg/m2Obese ≥30 kg/m2Pa
Number of patients (%)1,739 (27)3,384 (53)1,304 (20)
Age, median (IQR; y)64 (59–68)63 (58–67)62 (57–66)0.0001
PSA, median (IQR), ng/mL5.8 (4.5–7.4)5.7 (4.4–7.3)5.7 (4.3–7.3)0.06
Race, n (%)0.002†
 White1,561 (90)3,136 (93)1,197 (92)
 Black33 (2)56 (2)30 (2)
 Other145 (8)192 (6)77 (6)
DRE findings, n (%)0.58†
 Not suspicious1,669 (96)3,265 (96)1,252 (96)
 Suspicious for cancer70 (4)119 (4)52 (4)
TRUS volume, median (IQR), cc41 (32–54)44 (33–57)46 (35–59)0.0001
Total cores on baseline biopsy (IQR)8 (6–10)9 (6–10)10 (6–10)0.012
2-year biopsy type, n (%)0.717†
 Protocol-mandated1,565 (90)3,059 (90)1,185 (91)
 Off-study174 (10)325 (10)119 (9)
  • aP value assessed by the Kruskal–Wallis test unless otherwise specified.